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Open access under CC BY license.Glossary
Ataxia: the word comes from the Greek language and refers to a neurological
loss of voluntary coordination of muscular movement. Ataxia is a nonspecific
clinical manifestation that implies dysfunction of different parts of the nervous
system that coordinate movement, such as the cerebellum. Ataxias can affect
anyone of any age and can be both recessive or dominant.
Linear motifs: are short, conserved motifs involved in recognition and
targeting functions. These motifs are linear, in that they do not involve 3D
organization with sequence-wise distant segments of the molecule. Examples
are phosphorylation motifs and NLSs.
Misfolding diseases: a group of diseases caused by protein aggregation and
misfolding. Examples are Alzheimer’s and Parkinson’s diseases.
Oligonucleotide-binding (OB) fold: is a compact structural motif frequently
found in proteins involved in nucleic acid recognition. Structural comparison
of all OB fold/nucleic acid complexes solved to date confirms the low degree of
sequence similarity among members of this family while highlighting several
structural determinants common to most of these OB folds.
Polyglutamine diseases: are a family of neurodegenerative diseases caused by
the anomalous expansion of a CAG triplet repeat in a specific gene. This leads
to an expanded tract of glutamines in the corresponding gene products, which
makes the carrier proteins highly fibrillogenic. These diseases include
Huntington disease, spinobulbar muscular atrophy, dentatorubral-pallidoluy-
sian atrophy, and several spinocerebellar ataxias.
Protein chameleon: proteins or protein regions that can adopt multiple local or
global folds usually because of different environments or sequence variations.
This possibility is thought to facilitate evolutionary transitions in protein
structure and function. It is rather unusual to observe different conformations
(asymmetric subunits) in crystal structures.
Protomer: the term used in structural biology to refer to the smallest subunit
that assembles in a defined stoichiometry to form an oligomer. It is, forUnderstanding how proteins protect themselves from
aberrant aggregation is of primary interest for under-
standing basic biology, protein biochemistry, and hu-
man disease. We discuss the paradigmatic example of
ataxin-1 (Atx1), the protein responsible for neurodegen-
erative spinocerebellar ataxia type 1 (SCA1). This disease
is part of the increasing family of pathologies caused by
protein aggregation and misfolding. We discuss the
importance of protein–protein interactions not only in
the nonpathological function of Atx1 but also in protect-
ing the protein from aggregation and misfolding. The
lessons learned from Atx1 may lead to a more general
understanding of the cell’s protective strategies against
aggregation. The obtained knowledge may suggest a
new perspective for designing specific therapeutic
strategies for the cure of misfolding diseases.
Cellular mechanisms of protection from protein
aggregation
The increasing realization that protein aggregation plays a
predominant role in the development of a number of dis-
eases parallels an increasing interest in the mechanisms
that protect proteins from this often unwanted phenome-
non. Although much has been said about these protection
mechanisms, and several possible strategies that the cell
may take in combating protein aggregation have been
suggested [1–4], our knowledge of the topic remains limit-
ed. One of the most interesting hypotheses is that inter-
actions with other cellular partners could have a leading
role in preventing protein aggregation [3,5]. Several exam-
ples seem to support this hypothesis. It has, for instance,
been observed that binding to ligands, including nucleic
acids, prevents misfolding of the oncogene p53 [4].0166-2236     
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interactions.Similarly, the protein ataxin-3 has been found to be pro-
tected from aggregation when interacting with the natural
cellular partner ubiquitin [6]. These examples in turn
suggest that normal function and aberrant aggregation
are competing pathways [7].
In this review, we discuss the paradigmatic example
of Atx1. This protein provides a unique illustration of
how protein–protein interactions can sort the ‘fate’ of
a protein. Atx1 is responsible for SCA1 (OMIM #164400)instance, the monomeric subunit in a dimer.
Spinocerebellar ataxias (SCAs): are progressive neurodegenerative diseases
with multiple types, each of which could be considered a disease in its own right.
Structural domains: are a conserved part of a given protein sequence that can
evolve, function, and exist independently of the rest of the protein chain. Each
domain forms a compact 3D structure and often can be independently stable
and folded.
U2AF (U2 auxiliary factor) homology motif (UHM): is an RNA recognition
domain that binds to tryptophan-containing linear peptide motifs (ULMs) in
several nuclear proteins.
UHM ligand motif (ULM): is a short induced fit linear motif that mediates
dynamic interactions between splicing factors.
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Review Trends in Neurosciences April 2014, Vol. 37, No. 4[8] (for a definition of ataxia, see the Glossary). SCA1 is a
late onset autosomal dominant neurodegenerative disor-
der characterized by cerebellar ataxia and associated
with varying degrees of oculomotor abnormalities, pyra-
midal and extrapyramidal features, peripheral neuropa-
thy, and cognitive impairment [9]. Until a link with
disease was established, Atx1 had largely been over-
looked. However, over the last decade or so, a substantial
amount of research into the structure and function of
Atx1 has started to provide a clearer picture of the
cellular role of this protein [10,11].
In the following sections, we review our current knowl-
edge of Atx1 and place these observations within the
context of the protection mechanisms against aggregation.
We show how the normal function of the protein, together
with its unusual structural properties, determine its
cellular function/dysfunction and how aggregation is
mediated by multiple regions acting in cooperation. We
believe that this example may open a new perspective for
the study of SCA1 and other misfolding diseases and
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Figure 1. Expansion of a polyglutamine (polyQ) tract in specific proteins is associated wi
name, pathological threshold, and protein architecture. The position of polyQ in the seq
Schematic representation of the disease mechanism. When the repeat number is lowe
when it is above the threshold, the carrier proteins aggregate and misfold with conseq
212Atx1 is a member of the polyglutamine expansion
diseases
Atx1 is, together with the above mentioned ataxin-3, a
member of the family of proteins that contain a polygluta-
mine (polyQ) tract and are implicated in genetic neurode-
generative diseases [12] (Figure 1A). These pathologies are
caused by the anomalous expansion of a polymorphic tract of
polyQ, which, when above a threshold of approximately 37
repeats, causes aggregation that is ultimately associated
with cell toxicity and neuronal death [12] (Figure 1B). Al-
though rare and diversified in symptoms, these diseases are
dominant and currently incurable. Several lines of evidence
suggest that polyQ expansion is the necessary event for
disease development: attachment of a polyQ stretch to an
otherwise healthy protein is sufficient to cause toxicity;
interruption of the polyQ tract by even one non-glutamine
amino acid appreciably slows down disease and the age at
disease onset correlates inversely with the number of unin-
terrupted polyQ repeats [13]. It has however been recog-
nized that, in addition to polyQ, other regions significantly
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Figure 2. The structure of Atx1. (A) A schematic representation of the Atx1 architecture. The protein is represented as a horizontal bar on which the position of the polyQ
motif, the AXH domain and S776 are indicated. The interactions formed with various cellular partners are also listed near the interacting motif. (B) The crystal structure of
the AXH domain (PDB accession code 1oa8, [21]). In the crystallographic asymmetric unit, there are two dimers, which form a dimer of dimers (indicated in the figure with
alternated colors). (C) Structure of the dimer rotated by 45 degrees around the axis perpendicular to the plane as compared to the view in (B). The overall arrangement is
antiparallel with the termini being sandwiched in the dimer interface like in two touching left hands. The symmetry is however incomplete and the individual protomers
differ by local details. Most of the differences are grouped at the N termini. Abbreviations: Atx1, ataxin-1; CIC, Capicua; NLS, nuclear localization signal; PDB, Protein Data
Bank; polyQ, polyglutamine; UHM, U2AF (U2 auxiliary factor) homology motif; ULM, UHM ligand motif.
Review Trends in Neurosciences April 2014, Vol. 37, No. 4in studying Atx1 stems not only from the desire of finding a
cure for SCA1 but also because, being one of the small
members of the polyQ family, Atx1 is an excellent model
for understanding the behavior of the whole family [14].
Atx1 contains intrinsically unfolded regions and a
chameleon domain
Atx1 is a predominantly nuclear, ubiquitous protein well
conserved in vertebrates [15]. Human Atx1 is 816 amino
acids long although its length can increase depending on
the length of the polyQ tract, which varies from six to circa
44 glutamine repeats in the normal population and up to
about 83 uninterrupted glutamines in SCA1 patients
[10,12,13] (Figure 2A).
Prediction of the structure of Atx1 based on the amino
acid sequence indicates that Atx1 is predominantly an
intrinsically unstructured protein [14]. The only globular
domain present in the protein, named AXH (SMART
SM00536), is an independently folded motif of approxi-
mately 120 amino acids that was identified on the bases of
sequence conservation across species and secondary struc-
ture prediction [16]. According to the human Atx1 se-
quence (UniProtKB/Swiss-Prot No. P54253 +1), this
domain spans residues 567–689 [16]. The long N-terminal
region 1–566 contains the low complexity polymorphic
polyQ tract starting at residue 197 and one of the two
experimentally verified phosphorylation sites [14]. The
polyQ stretch is expected to be unstructured as shown
by circular dichroism (CD) and nuclear magnetic resonance
(NMR) spectroscopy [17]. The C terminus (residues690–816) is also predicted to be unstructured and contains
several linear motifs, either clustered in proximity or
including the phosphorylable S776, which are extremely
important for protein localization [15,18] and recognition
of biological partners [19,20].
The intrinsic tendency of Atx1 to degradation and ag-
gregation even when in its non-expanded form has so far
hampered the possibility of expressing and purifying the
recombinant full-length protein in an intact mono-disperse
form suitable for a structural characterization of its con-
formational ensemble. However, it was possible to produce
the AXH domain in isolation and to investigate its struc-
ture both in the crystal and in solution. The crystal struc-
ture revealed the open barrel typical of an oligonucleotide-
binding (OB) fold, a structural motif involved in nucleic
acid and protein recognition [21]. The crystal asymmetric
unit contains a dimer of dimers (Figure 2B). The individual
protomers are arranged in an antiparallel fashion with the
N termini sandwiched between the dimer interface. The
dimer structure resembles two left hands (the protomers)
touching each other in an antiparallel fashion so that the
two thumbs (corresponding to the N termini) are close in
space and parallel (Figure 2C). The protomers are nonsym-
metric having the first approximately 20 N-terminal ami-
no acids of the individual protomers adopting different
conformations and thus defining asymmetric dimer inter-
faces. The unusually variable structure of the N terminus
of the domain makes the AXH a unique case of a protein
‘chameleon’, that is, a protein that is able to adopt distinct
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Figure 3. Protein–protein interaction seems to be an important element that
determines protein function. (A) Normal function as a competing pathway to
aggregation. (B) Schematic representation of the role of phosphorylation of S776
as a molecular switch. When S776 is non-phosphorylated, ataxin-1 (Atx1) is part of
a large multiprotein complex and is likely to engage in multiple cooperative
interactions with spliceosomal factors being thus protected against aggregation.
When it is phosphorylated, it interacts with 14-3-3 and other such proteins and
remains more prone to aggregation.
Review Trends in Neurosciences April 2014, Vol. 37, No. 4domain also in solution was demonstrated by analytical
ultracentrifugation studies, which showed that the
predominant species in the low micromolar range of con-
centrations is dimeric, although in co-presence with higher
molecular species [16,21]. In agreement with these data,
small angle X-ray scattering (SAXS) confirmed the exis-
tence of a complex equilibrium between monomeric, dimer-
ic, and tetrameric species in solution [22]. Taken together,
these findings indicate a strong tendency of the AXH
domain to dimerize and suggest that the dimerization
observed for the AXH could account for the known self-
association of the full-length protein observed in the cell
[23].
In search of Atx1 function: a dual role in transcription
and RNA metabolism
Not long after the SCA1 gene was identified [24], it was
discovered that expanded Atx1 has to enter the nucleus of
Purkinje cells to become pathogenic [15]. Subsequently,
analysis of a transgenic mouse model for SCA1 showed
that gene expression is dysregulated at a very early stage
of the disease, when neurological hallmarks are still un-
detectable [25,26]. Several transcriptional corepressors
were also identified as modulators of the Atx1-mediated214eye phenotype in a genetic screen in Drosophila [27].
Overall, these observations suggested that Atx1 is involved
in transcription regulation and that SCA1 pathogenesis
could be the result of alterations in gene expression, rather
than or in addition to the gain of function mechanism
triggered by polyQ expansion.
Using a general read-out assay for repression of tran-
scription it was shown that both full-length Atx1 and the
isolated AXH domain repress transcription when tethered
to DNA [28,29]. However, interaction with DNA must be
mediated by other transcription factors because crosslink-
ing experiments excluded a direct binding between Atx1
and DNA [29].
Atx1 has been described as modulating the function of
several transcriptional regulators, often by means of direct
protein–protein interactions. The partners identified so far
include polyQ binding protein-1 (PQBP1) [30], the media-
tor of retinoid and thyroid hormone receptors SMRT/
SMRTER [28], the repressor Capicua (CIC) [31], the tran-
scription factors Senseless/Gfi-1 [32] and Sp1 [33], tran-
scriptional complexes like Tip60-RORa [34], LANP-E4F
[35] and HDAC-MEF2 [36], and, more recently, CBF1, a
Notch signaling pathway transcription factor [37]. Several
of these interactions map to the AXH domain (Figure 2A)
and have been shown to be positively or negatively affected
by expansion of the polyQ with consequent perturbation of
the associated transcriptional pathway.
In addition to a role in transcriptional regulation
[10,12], Atx1 is an RNA binding protein. It recognizes
RNA homo-polymers in a manner that depends on the
length of the polyQ tract [38]. The AXH domain was also
identified as the region responsible for RNA homo-poly-
mer binding, exhibiting the same preference as the full-
length Atx1 [16]. Further support for a role of Atx1 in
RNA metabolism is provided by investigations of the
protein interactome, most of which consists of proteins
involved in RNA binding. Atx1 was shown to recruit the
mRNA export factor TAP/NXF1 in an RNA-dependent
manner, suggesting a role in processing and/or exporting
specific mRNAs to the cytoplasm [39]. Interestingly, the
majority of the RNA binding proteins thereafter identi-
fied as Atx1 binding partners, that is, RBM9/FOX2,
A2BP/FOX-1 [40], RBM17/SPF45 and U2AF65 [41],
are splicing factors. In the case of RBM17 and
U2AF65, the interaction was mapped onto the short
linear UHM ligand motif (ULM) in the C terminus of
Atx1, a sequence known to be involved in recognition of
the splicing factor U2AF (U2 auxiliary factor) homology
motif (UHM) domain [20]. It was also shown that Atx1
has a positive effect on U2AF65 splicing [20] and that
overexpression of Atx1 positively affects splicing of tran-
scripts of the other polyQ-containing protein ataxin-2 by
RBM9/FOX2 [42]. These findings strongly suggest a
specific role of Atx1 in pre-mRNA processing.
Aberrant aggregation: non-polyQ regions have a role in
aggregation and disease
Although polyQ expansion plays a predominant role in
disease, it has been demonstrated that polyQ expansion is
a necessary but not sufficient condition for disease devel-
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Figure 4. Interaction with the protein CIC suggests a possible approach to drug design. (A) Comparison of the structures of the AXH domain in the dimer (left panel, PDB
accession code 1oa8, [21]) and of a complex with a synthetic peptide spanning the sequence of the CIC N terminus (right panel, PDB accession code 2m41 [49]). The
structure of the complex corresponds, in our analogy, to having the palm wide open because the N terminus is now pushed out. (B) The same as in (A) but representing the
AXH monomers with the Van der Waals surface. The N terminus of the other protomer in the dimeric form (in green) packs in the same groove occupied by the CIC peptide
(in red). The two interacting chains adopt opposite orientations. [Note that the two structures were independently solved in the crystal (the dimer) and in solution (the
complex). This explains the different looking van der Waals envelope that is determined by the side chain rotamers.] (C) A schematic model of the equilibrium between
multiple species of the AXH domain in solution and how this can relate to aggregation. The presence of CIC (shown as a red square) shifts the equilibrium towards the
monomeric form thus stabilizing the protein against aggregation. Abbreviations: CIC, Capicua; PDB, Protein Data Bank.
Review Trends in Neurosciences April 2014, Vol. 37, No. 4distant from the polyQ tract contribute to protein aggre-
gation [12].
One such region is the AXH domain [29] and, C terminal
to it, the stretch that contains phosphorylable S776 and
the nuclear localization signal (NLS). These motifs seem to
be particularly important for the formation of inclusions
and SCA1 progression [12,15,19,20,29,43]. For example, it
was demonstrated that the isolated AXH domain pos-
sesses an intrinsic ability to aggregate and that, in vitro,
the domain spontaneously forms fibers even in the absence
of destabilizing conditions, whereas in eukaryotic cells its
propensity to multimerization positively influences the
aggregation of the expanded full-length protein [29]. Thus,
it has been suggested that, in addition to polyQ, AXH may
act as a second aggregation ‘hotspot’. The possibility of
forming dimers, tetramers, and higher molecular species
observed at the level of the isolated AXH seems to be on-
pathway to fiber formation. This could explain why over-
expression of non-expanded Atx1 (i.e., 30 glutamines) inflies and mice causes phenotypes similar to those caused
by overexpression of Drosophila Atx1, which lacks the
polyQ tract, but different from those observed for polyQ
peptides [27,32]. The evidence of an involvement of AXH
as an independent aggregation hotspot is so compelling as
to allow Zohgbi and coworkers to suggest that ‘the AXH
domain but not the expanded polyQ tract could be neces-
sary to generate the Atx1 gain-of-function phenotype in
flies’ and be required for SCA1 pathogenesis [32].
Therefore, the pathological behavior of Atx1 is a conse-
quence of a complex crosstalk between several different
regions. This is not the first example of a protein with
multiple aggregation sites comprising both intrinsically
unfolded and globular domains [44].
Defense mechanisms: role of protein–protein
interactions in disease development
Protein aggregation has been suggested to be a competing
pathway of normal function and therefore of functional215
Review Trends in Neurosciences April 2014, Vol. 37, No. 4protein–protein interactions [7] (Figure 3A). This state-
ment appears to hold true for Atx1; although the subject
is still debated, SCA1 appears to be better explained by a
loss of function caused by alterations of native protein–
protein interactions via protein aggregation than by the
acquisition of novel aberrant interactions acquired
through polyQ expansion [41,45]. A direct competition
between interactions with other cellular partners and
self-association is also in agreement with the observation
that transcription dysregulation occurs already at the
very early stages of the disease [25,27,46]. In this view,
the characterization of native interactions of Atx1 with
its cellular partners not only is relevant to identify the
protein function but could also be important for under-
standing how interacting proteins modulate aggregation
and pathogenesis.
As mentioned above, most of the known interactions of
Atx1 with its cellular partners have been mapped onto the
C terminus of the protein, either on the AXH domain or on
short linear motifs around the phosphorylable S776. Phos-
phorylation of S776, in particular, acts as a molecular
switch that allows the protein to discriminate between
different binding partners [20] (Figure 3B). The phosphor-
ylation state of S776, which, notably, is a residue sequence-
wise very distant from polyQ, has been shown to be neces-
sary for pathogenesis in the presence of expansion [19].
Among the interacting partners of Atx1 in this region are
the molecular adaptor 14-3-3, which specifically binds
S776-phosphorylated Atx1, and the splicing factors
U2AF65 and SPF45, which recognize the non-phosphory-
lated protein [20,47]. Based on this evidence, we formulat-
ed the hypothesis that participation in interactions with
SPF45 and U2AF65 that are components of the large
dynamic spliceosome machine could play a protective role
against self-association of expanded Atx1 [19,20,47]. This
would prevent or reduce self-association of Atx1 to an
extent that would allow efficient clearance by the protea-
some pathway machinery. Conversely, when Atx1 is S776-
phosphorylated and recruited by the relatively small 14-3-
3, the interaction with the spliceosome complex is ham-
pered and expanded Atx1 becomes available to self-associ-
ation. This could be a possible mechanism of defense from
aggregation.
Can protein–protein interactions be used for therapeutic
purpose?
An even more interesting example of how a cellular part-
ner can counteract the intrinsic propensity of Atx1 to-
wards aggregation is that of the transcriptional
repressor CIC. This protein forms a stable complex with
wild type Atx1 and participates in the formation of a large
native complex in mouse cerebellum [31,41]. PolyQ expan-
sion attenuates the formation of the Atx1–CIC complex
and weakens the corepressive function exerted by the
complex [31,41,46].
Recognition between Atx1 and CIC has been mapped
onto the AXH domain and a short linear motif located in
the N terminus of CIC [31]. The structures of the AXH
complexes with peptides of different lengths spanning
the CIC sequence were determined both by X-ray crys-
tallography and solution NMR spectroscopy [48,49]. In216the complex, the structure of AXH changes once again,
thus confirming the extraordinary structural plasticity of
this chameleon protein: the N terminus of monomeric
AXH no longer packs against the rest of the domain (as if
the hand opened up; Figures 2C and 4A). The peptide
replaces, in a reversed orientation, the N terminus of the
other dimer protomer, shielding the hydrophobic core of
the AXH domain from solvent exposure in a similar way
as observed in the dimer (Figure 4B). This shows that
the AXH domain is capable of establishing palindromic
interactions.
The minimal CIC sequence necessary and sufficient to
recognize AXH with nanomolar affinity was identified in
the stretch V34–L44 with W37 and L40 of CIC being the
only residues significantly decreasing the peptide affinity
when mutated into alanine [49]. Interestingly, interaction
with the CIC peptides competes with AXH dimerization,
but the precise effect depends on the length of the peptide.
In the crystal structure, binding of a longer CIC peptide
(residues 28–48) disrupts the AXH dimer but allows an-
other form of dimerization that is, in turn, mediated by CIC
[48]. In the solution structure that was solved using the
minimal CIC sequence necessary for binding with high
affinity (residues 34–44) dimerization is blocked altogether
(Figure 4A) [49]. This is caused by complex formation with
the shorter peptide, which results in the stabilization of
monomeric AXH and prevents aggregation as measured
via analytical gel filtration recorded under the same con-
ditions in which the AXH domain in the ‘free’ form aggre-
gates spontaneously and forms amyloid-like fibers after 1
week. When the complex is formed, aggregation is ham-
pered so completely that the complex remains monodis-
perse at 378C for at least 30 days.
These results have the potential to be translated into
a treatment for SCA1. If what we observe at the level of
the isolated domain could be transferred to the full-
length protein, the CIC sequence found to bind Atx1
with high affinity could be used directly as a mould to
design compounds able to stabilize monomeric Atx1 and
prevent aggregation. It would be particularly interesting
to design peptidomimetic molecules based on the CIC
sequence that would be more suitable to this aim than
easily degradable peptides (Box 1). This strategy could
result in an approach very specific to SCA1 and therefore
very different from the use of generic anti-aggregation
molecules, such as polyols, methylene blue, or other such
compounds [2].
Concluding remarks
Atx1 provides an interesting example of how proteins are
protected from aberrant aggregation. The example stres-
ses once again the importance of protein–protein interac-
tions in determining and diversifying protein function. It
also shows the importance of studying the nonpathological
function of proteins implicated in misfolding diseases in
parallel with the pathological properties. A more general
understanding of their cellular role seems indeed to be
essential to suggest new, specific strategies for drug devel-
opment. We thus hope that the message contained in the
specific example of Atx1 will be inspirational for other
proteins of the misfolding disease family.
Box 1. Outstanding questions
 Role of Atx1 in RNA metabolism: More experiments will be needed
to assess the specific role of the protein in RNA metabolism. The
current evidence supports more than one function and partner
specificity in different cellular localizations [20,38–41]. New in vivo
experiments as complemented by in vitro work should clarify the
role of all the binding partners in a time-resolved way.
 Gain and loss of function: A certain degree of ambiguity, some-
times even among the same authors, remains on whether SCA1 is
caused by a gain or a loss of function. It was argued that polyQ
expansion favors the formation of specific protein complexes,
which contribute to SCA1 through a gain-of-function mechanism.
However, at the same time, it was also noted that polyQ expansion
attenuates the formation of other protein complexes (for instance
that with CIC), contributing to SCA1 through a partial loss-of-
function mechanism [41,45]. It will thus be important to clarify this
aspect further and understand the extent and circumstances that
may favor one or the other mechanism.
 Role of AXH domain in aggregation: Although it is clear that AXH
has a role in aggregation, it is still unclear whether blocking its
aggregation could be beneficial for the aggregation of full-length
Atx1 especially in the presence of polyQ expansion. Further studies
will be required to ascertain whether the ‘protective’ effect
produced by interaction with the peptide ligand from CIC is also
observed in the context of the expanded full-length protein. This
hypothesis could be tested, for instance, by transient co-transfec-
tion of the protein and the peptide to test whether the aggregation
foci formed by Atx1 are cleared/reduced in the presence of the
interaction.
 Drug design in SCA1: Once the role of AXH dimerization in
aggregation is clarified, it will be of particular interest to design
peptidomimetic molecules that mimic the features of the CIC
peptides. This strategy could result in an approach specific to SCA1
that could thus be more effective than the use of generic anti-
aggregation molecules, such as polyols, methylene blue, or other
such compounds [2]. An even more powerful approach could be that
based on structure–activity relationship (SAR) by NMR originally
developed by Stephen Fesik and coworkers [50]. With this technique,
compounds with higher affinities could be obtained by tethering,
with a linker of suitable length, the CIC-like compound with ligands
that prevent polyQ aggregation, thus obtaining even more specific
drugs. At the same time, a wider screening of mutations on the
peptide may be important to provide better bases for drug design.
Review Trends in Neurosciences April 2014, Vol. 37, No. 4Acknowledgments
The authors wish to thank the Crick Institute for its commitment to
excellence. The work was supported by the MRC (Grant ref.
U117584256).
References
1 Cohen, F.E. and Kelly, J.W. (2003) Therapeutic approaches to protein-
misfolding diseases. Nature 426, 905–909
2 Ehrnhoefer, D.E. et al. (2008) EGCG redirects amyloidogenic
polypeptides into unstructured, off-pathway oligomers. Nat. Struct.
Mol. Biol. 15, 558–566
3 Shao, J. and Diamond, M.I. (2007) Polyglutamine diseases: emerging
concepts in pathogenesis and therapy. Hum. Mol. Genet. 16, R115–
R123
4 Silva, J.L. et al. (2010) Ligand binding and hydration in protein
misfolding: insights from studies of prion and p53 tumor suppressor
proteins. Acc. Chem. Res. 43, 271–279
5 Boeddrich, A. et al. (2006) An arginine/lysine-rich motif is crucial for
VCP/p97-mediated modulation of ataxin-3 fibrillogenesis. EMBO J. 25,
1547–1558
6 Masino, L. et al. (2011) Functional interactions as a survival strategy
against abnormal aggregation. FASEB J. 25, 45–54
7 Pastore, A. and Temussi, P.A. (2012) The two faces of Janus: functional
interactions and protein aggregation. Curr. Opin. Struct. Biol. 22, 30–
37
8 Hamosh, A. et al. (2005) Online Mendelian Inheritance in Man
(OMIM), a knowledgebase of human genes and genetic disorders.
Nucleic Acids Res. 33, D514–D517
9 Donato, S.D. et al. (2012) Spinocerebellar ataxia type 1. Handb. Clin.
Neurol. 103, 399–421
10 de Chiara, C. and Pastore, A. (2011) Polyglutamine diseases and
neurodegeneration: the example of ataxin-1. In Supramolecular
Structure and Function 10 (Brnjas-Kraljevic, J. and Pifat-Mrzljak,
G., eds), pp. 87–99, Springer
11 Orr, H.T. (2012) Cell biology of spinocerebellar ataxia. J. Cell Biol. 197,
167–177
12 Zoghbi, H.Y. and Orr, H.T. (2009) Pathogenic mechanisms of a
polyglutamine-mediated neurodegenerative disease, spinocerebellar
ataxia type 1. J. Biol. Chem. 284, 7425–7429
13 Menon, R.P. et al. (2013) The role of interruptions in polyQ in the
pathology of SCA1. PLoS Genet. 9, e1003648
14 de Chiara, C. and Pastore, A. (2011) Prediction and experimental
detection of structural and functional motifs in intrinsically
unfolded proteins. In Selected Works in Bioinformatics (Xia, X., ed.),
pp. 81-102, InTech15 Klement, I.A. et al. (1998) Ataxin-1 nuclear localization and
aggregation: role in polyglutamine-induced disease in SCA1
transgenic mice. Cell 95, 41–53
16 de Chiara, C. et al. (2003) The AXH module: an independently folded
domain common to ataxin-1 and HBP1. FEBS Lett. 551, 107–112
17 Masino, L. et al. (2002) Solution structure of polyglutamine tracts in
GST-polyglutamine fusion proteins. FEBS Lett. 513, 267–272
18 Lai, S. et al. (2011) 14-3-3 Binding to ataxin-1(ATXN1) regulates its
dephosphorylation at Ser-776 and transport to the nucleus. J. Biol.
Chem. 286, 34606–34616
19 Emamian, E.S. et al. (2003) Serine 776 of ataxin-1 is critical for
polyglutamine-induced disease in SCA1 transgenic mice. Neuron 38,
375–387
20 de Chiara, C. et al. (2009) Phosphorylation of s776 and 14-3-3 binding
modulate ataxin-1 interaction with splicing factors. PLoS ONE 4,
e8372
21 Chen, Y.W. et al. (2004) The structure of the AXH domain of
spinocerebellar ataxin-1. J. Biol. Chem. 279, 3758–3765
22 de Chiara, C. et al. (2013) Self-assembly and conformational
heterogeneity of the AXH domain of ataxin-1: an unusual example
of a chameleon fold. Biophys. J. 104, 1304–1313
23 Burright, E.N. et al. (1997) Identification of a self-association region
within the SCA1 gene product, ataxin-1. Hum. Mol. Genet. 6, 513–518
24 Banfi, S. et al. (1994) Identification and characterization of the gene
causing type 1 spinocerebellar ataxia. Nat. Genet. 7, 513–520
25 Lin, X. et al. (2000) Polyglutamine expansion down-regulates specific
neuronal genes before pathologic changes in SCA1. Nat. Neurosci. 3,
157–163
26 Serra, H.G. et al. (2004) Gene profiling links SCA1 pathophysiology to
glutamate signaling in Purkinje cells of transgenic mice. Hum. Mol.
Genet. 13, 2535–2543
27 Fernandez-Funez, P. et al. (2000) Identification of genes that modify
ataxin-1-induced neurodegeneration. Nature 408, 101–106
28 Tsai, C.C. et al. (2004) Ataxin 1, a SCA1 neurodegenerative disorder
protein, is functionally linked to the silencing mediator of retinoid and
thyroid hormone receptors. Proc. Natl. Acad. Sci. U.S.A. 101, 4047–
4052
29 de Chiara, C. et al. (2005) Polyglutamine is not all: the functional role of
the AXH domain in the ataxin-1 protein. J. Mol. Biol. 354, 883–893
30 Okazawa, H. et al. (2002) Interaction between mutant ataxin-1 and
PQBP-1 affects transcription and cell death. Neuron 34, 701–713
31 Lam, Y.C. et al. (2006) ATAXIN-1 interacts with the repressor Capicua in
its native complex to cause SCA1 neuropathology. Cell 127, 1335–1347
32 Tsuda, H. et al. (2005) The AXH domain of Ataxin-1 mediates
neurodegeneration through its interaction with Gfi-1/Senseless
proteins. Cell 122, 633–644217
Review Trends in Neurosciences April 2014, Vol. 37, No. 433 Goold, R. et al. (2007) Down-regulation of the dopamine receptor D2 in
mice lacking ataxin 1. Hum. Mol. Genet. 16, 2122–2134
34 Serra, H.G. et al. (2006) RORalpha-mediated Purkinje cell
development determines disease severity in adult SCA1 mice. Cell
127, 697–708
35 Cvetanovic, M. et al. (2007) The role of LANP and ataxin 1 in E4F-
mediated transcriptional repression. EMBO Rep. 8, 671–677
36 Bolger, T.A. et al. (2007) The neurodegenerative disease protein ataxin-
1 antagonizes the neuronal survival function of myocyte enhancer
factor-2. J. Biol. Chem. 282, 29186–29192
37 Tong, X. et al. (2011) Ataxin-1 and Brother of ataxin-1 are components
of the Notch signalling pathway. EMBO Rep. 12, 428–435
38 Yue, S. et al. (2001) The spinocerebellar ataxia type 1 protein, ataxin-1,
has RNA-binding activity that is inversely affected by the length of its
polyglutamine tract. Hum. Mol. Genet. 10, 25–30
39 Irwin, S. et al. (2005) RNA association and nucleocytoplasmic shuttling
by ataxin-1. J. Cell Sci. 118, 233–242
40 Lim, J. et al. (2006) A protein-protein interaction network for human
inherited ataxias and disorders of Purkinje cell degeneration. Cell 125,
801–814
41 Lim, J. et al. (2008) Opposing effects of polyglutamine expansion
on native protein complexes contribute to SCA1. Nature 452,
713–71821842 Welzel, F. et al. (2012) FOX-2 dependent splicing of ataxin-2 transcript
is affected by ataxin-1 overexpression. PLoS ONE 7, e37985
43 Skinner, P.J. et al. (2002) Amino acids in a region of ataxin-1 outside of
the polyglutamine tract influence the course of disease in SCA1
transgenic mice. Neuromol. Med. 1, 33–42
44 Saunders, H.M. et al. (2011) Flanking domain stability modulates the
aggregation kinetics of a polyglutamine disease protein. Protein Sci. 20,
1675–1681
45 Orr, H.T. (2012) SCA1-phosphorylation, a regulator of Ataxin-1
function and pathogenesis. Prog. Neurobiol. 99, 179–185
46 Crespo-Barreto, J. et al. (2010) Partial loss of ataxin-1 function
contributes to transcriptional dysregulation in spinocerebellar
ataxia type 1 pathogenesis. PLoS Genet. 6, e1001021
47 Menon, R.P. et al. (2012) The importance of serine 776 in Ataxin-1
partner selection: a FRET analysis. Sci. Rep. 2, 919
48 Kim, E. et al. (2013) Structural basis of protein complex formation and
reconfiguration by polyglutamine disease protein Ataxin-1 and
Capicua. Genes Dev. 27, 590–595
49 de Chiara, C. et al. (2013) Protein-protein interactions as a strategy
towards protein-specific drug design: the example of Ataxin-1. PLoS
ONE 8, e76456
50 Shuker, S.B. et al. (1996) Discovering high-affinity ligands for proteins:
SAR by NMR. Science 274, 1531–1534
